APA (7th ed.) Citation

W, B., P, L., CR, H., PPJ, P., & J, J. (2025). Representativeness and adverse event reporting in late-phase clinical trials for rifampin-susceptible tuberculosis: A systematic review. The Lancet. Infectious diseases, 25(2), e86. https://doi.org/10.1016/S1473-3099(24)00597-8

Chicago Style (17th ed.) Citation

W, Burman, Luczynski P, Horsburgh CR, Phillips PPJ, and Johnston J. "Representativeness and Adverse Event Reporting in Late-phase Clinical Trials for Rifampin-susceptible Tuberculosis: A Systematic Review." The Lancet. Infectious Diseases 25, no. 2 (2025): e86. https://doi.org/10.1016/S1473-3099(24)00597-8.

MLA (9th ed.) Citation

W, Burman, et al. "Representativeness and Adverse Event Reporting in Late-phase Clinical Trials for Rifampin-susceptible Tuberculosis: A Systematic Review." The Lancet. Infectious Diseases, vol. 25, no. 2, 2025, p. e86, https://doi.org/10.1016/S1473-3099(24)00597-8.